LH:NYE-Laboratory Corporation of America Holdings (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 227.84

Change

-0.77 (-0.34)%

Market Cap

USD 12.76B

Volume

0.51M

Analyst Target

USD 228.47
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Laboratory Corp of America Holdings is a healthcare diagnostics company. The Company along with its subsidiaries provides clinical laboratory services and end-to-end drug development support.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

+0.61 (+0.27%)

USD 165.08B
A Agilent Technologies Inc

+0.09 (+0.07%)

USD 40.09B
IQV IQVIA Holdings Inc

+1.84 (+0.93%)

USD 36.13B
DGX Quest Diagnostics Incorporated

-0.16 (-0.10%)

USD 17.09B
QGEN Qiagen NV

+0.15 (+0.34%)

USD 10.26B
CRL Charles River Laboratories

-0.38 (-0.20%)

USD 9.50B
VNRX Volitionrx Ltd

-0.07 (-9.75%)

USD 0.06B
ENZ Enzo Biochem Inc

-0.02 (-2.85%)

USD 0.04B
TMO Thermo Fisher Scientific Inc

+1.24 (+0.24%)

N/A
MTD Mettler-Toledo International I..

+3.65 (+0.30%)

N/A

ETFs Containing LH

CAMX Cambiar Aggressive Value .. 4.36 % 0.00 %

+0.20 (+0.00%)

USD 0.06B
EDOC:LSE Global X Telemedicine & D.. 4.19 % 0.00 %

-0.06 (0.00%)

USD 2.08M
EDOG:LSE Global X Telemedicine & D.. 4.19 % 0.00 %

+0.01 (+0.00%)

USD 0.42M
DDOC:F Global X Telemedicine & D.. 4.13 % 0.00 %

+0.25 (+0.00%)

USD 4.62M
EDOC:SW Global X Telemedicine & D.. 3.97 % 0.00 %

N/A

N/A
XHS SPDR® S&P Health Care Se.. 2.26 % 0.35 %

-0.09 (0.00%)

USD 0.07B
RSPH Invesco S&P 500 Equal Wei.. 1.81 % 0.00 %

+0.04 (+0.00%)

USD 0.88B
ZUH:CA BMO Equal Weight US Healt.. 1.54 % 0.39 %

+0.29 (+0.00%)

CAD 0.23B
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.34 (+0.00%)

N/A
BVNSC 0.00 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

-0.10 (0.00%)

USD 0.04B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

-0.04 (0.00%)

USD 5.39M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.24% 62% D 40% F
Dividend Return 1.27% 71% C- 21% F
Total Return 1.51% 62% D 31% F
Trailing 12 Months  
Capital Gain 1.71% 69% C- 44% F
Dividend Return 1.29% 71% C- 21% F
Total Return 2.99% 69% C- 35% F
Trailing 5 Years  
Capital Gain 56.94% 67% D+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.94% 67% D+ 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 14.28% 77% C+ 74% C
Dividend Return 14.73% 85% B 71% C-
Total Return 0.45% 57% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 41.46% 15% F 24% F
Risk Adjusted Return 35.54% 62% D 50% F
Market Capitalization 12.76B 67% D+ 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.30 38% 14%
Price/Book Ratio 2.34 89% 37%
Price / Cash Flow Ratio 14.40 56% 28%
Price/Free Cash Flow Ratio 17.57 44% 23%
Management Effectiveness  
Return on Equity 5.43% 44% 44%
Return on Invested Capital 3.79% 22% 40%
Return on Assets 3.96% 44% 66%
Debt to Equity Ratio 51.49% 50% 61%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector